Publications en anglais

  1. Jacquillat C, Khayat D, Desprez-Curely JP, Weil M, Brocheriou C, Auclerc G, Chamseddine N, Bernard J. Non-Hodgkin’s lymphoma occurring after Hodgkin’s disease. Four new cases and a review of the literature. Cancer. 1984 Feb 1;53(3):459-62. Review. PubMed PMID: 6362816.

  1. Khayat D, Dux Z, Anavi R, Shlomo Y, Witz IP, Ran M. Circulating cellfree Fc gamma 2b/gamma 1 receptor in normal mouse serum: its detection and specificity. J Immunol. 1984 May;132(5):2496-501. PubMed PMID: 6201546.

  1. Richard C, Riou B, Berdeaux A, Fournier C, Khayat D, Rimailho A, Giudicelli JF, Auzepy P. Prospective study of the potentiation of acenocoumarol by amiodarone. Eur J Clin Pharmacol.1985;28(6):625-9. PubMed PMID: 4065185.

  1. Jacquillat C, Baillet F, Auclerc G, Khayat D, Blondon J, Auclerc MF, Facchin T, Lefranc JP, Weil M. Neoadjuvant chemotherapy of breast cancer. Drugs Exp Clin Res. 1986;12(1-3):147-52. PubMed PMID: 3525069.

  1. Jacquillat CI, Weil M, Auclerc G, Sellami M, Auclerc MF, Khayat D, Baillet F.Neoadjuvant chemotherapy in the conservative management of breast cancers: study of 143 patients. Recent Results Cancer Res. 1986;103:113-9. PubMed PMID: 3526473.

  1. Khayat D, Serban D, Dux Z, Schlomo Y, Jacquillat C. Role of infection in the modulation of mouse circulating soluble cell-free Fc gamma 2b/gamma 1 receptor. Scand J Immunol. 1986 Jul;24(1):83-91. PubMed PMID: 2941861.

  1. Khayat D, Geffrier C, Yoon S, Scigliano E, Soubrane C, Weil M, Unkeless JC,Jacquillat C. Soluble circulating Fc gamma receptors in human serum. A new ELISA assay for specific and quantitative detection. J Immunol Methods. 1987 Jun 26;100(1-2):235-41. PubMed PMID: 2955053.

  1. Jacquillat Cl, Baillet F, Weil M, Auclerc G, Housset M., Auclerc M.F, Sellami M., Jindani A, Thill L, Soubrane C, Khayat D. Results of a conservative treatment combining induction (Neoadjuvant) and consolidation chemotherapy, hormonotherapy and External and Interstitial Irradiation in 98 patients with locally advanced Breast Cancer (IIIA-IIIB) Cancer, 1988, 61 ; 10 : 1977-1982.

  1. Clavier J., Zabbe C, Kerbouche J.F, Gouva S, Khayat D, Weil M, Jacquillat Cl. Integracion de la quemotherapia, radiotherapia y cirurgia en el tratamento del cancer del pilmonas no de celulas pequenas. Rev. Cancer, 1987, 1; 4: 185-189.

  2. Jacquillat Cl, Weil M , Baillet F, Auclerc G, Jindani A , Housset M , Khayat D. A clinical trial of neoadjuvant chemotherapy and radiotherapy in 205 patients with breast cancer. Senologia, 1987, 2; 3: 93-99.

  1. Khayat D, Lokiec F, Bizzari JP, Weil M, Meeus L, Sellami M, Rouesse J, Banzet P, Jacquillat C. Phase I clinical study of the new amino acid-linked nitrosourea,S 10036, administered on a weekly schedule. Cancer Res. 1987 Dec 15;47(24 Pt 1):6782-5. PubMed PMID: 3677107.

  1. Khayat D, Le Cesne A, Weil M, Azar N, Cour V, Vu Thi Myle C, Auclerc G, Thill, Valantin X, Cohen-Aloro G, Langlois P, Bousquet JC, , Jacquillat C.Intra-arterial treatment of hepatic metastasis using the 5-Fluorouracil, Adriamycin, Mitomycin C (FAM) chemotherapeutic regimen. Reg. Cancer Treat, 1988, 1; 1: 62-64.

  1. Khayat D, Bizzari JP, Frenay M, Naman H, Weil M, Goupil A, Namer M, Rouesse J, Banzet P, Jacquillat C. Interim report of phase II study of new nitrosourea S 10036 in disseminated malignant melanoma. J Natl Cancer Inst. 1988 Nov2;80(17):1407-8. PubMed PMID: 3172267.

  1. Jacquillat C, Weil M, Auclerc G, Auclerc MF, Khayat D, Baillet F. Neoadjuvant chemotherapy in the conservative management of breast cancer: a study of 252 patients. Recent Results Cancer Res. 1989;115:36-42. PubMed PMID: 2516351.

  1. Deray G, Khayat D, Cacoub P, Bourbouze R, Musset L, Baumelou A, Jacquillat C,Jacobs C. The effects of diltiazem on methotrexate-induced nephrotoxicity. Eur J Clin Pharmacol. 1989;37(4):337-40. PubMed PMID: 2689182.

  1. Deray G, Khayat D, Bizzari JP, Jacquillat C. Renal hemodynamic and tubular effects of S 10036 (fotemustine) in man. Clin Nephrol. 1989 Sep;32(3):150. PubMed PMID: 2791369.

  1. Deray G, Khayat D, Jacquiaud C, Bizzari JP, Bourbouze R, Musset L, Jaudon MC, Baumelou B, Jacquillat C, Jacobs C. Renal effects of S10036 in man. Cancer Chemother Pharmacol. 1990;26(6):467-8. PubMed PMID: 2225319.

  1. Jacquillat C, Khayat D, Banzet P, Weil M, Avril MF, Fumoleau P, Namer M, Bonneterre J, Kerbrat P, Bonerandi JJ, et al. Chemotherapy by fotemustine in cerebral metastases of disseminated malignant melanoma. Cancer Chemother Pharmacol. 1990;25(4):263-6. PubMed PMID: 2403853.

  1. Rossignon MD, Khayat D, Royer C, Rouby JJ, Jacquillat C, Viars P. Functional and metabolic activity of polymorphonuclear leukocytes from patients with adult respiratory distress syndrome: results of a randomized double-blind placebo-controlled study on the activity of prostaglandin E1. Anesthesiology.1990 Feb;72(2):276-81. PubMed PMID: 2405741.

  1. Khayat D, Soubrane C, Andrieu JM, Visonneau S, Eme D, Tourani JM, Beldjord K,Weil M, Fernandez E, Jacquillat C. Changes of soluble CD16 levels in serum of HIV-infected patients: correlation with clinical and biologic prognostic factors. J Infect Dis. 1990 Mar;161(3):430-5. PubMed PMID: 2138203.

  1. Jacquillat C, Khayat D, Banzet P, Weil M, Fumoleau P, Avril MF, Namer M, Bonneterre J, Kerbrat P, Bonerandi JJ, et al. Final report of the French multicenter phase II study of the nitrosourea fotemustine in 153 evaluable patients with disseminated malignant melanoma including patients with cerebral metastases. Cancer1990 Nov 1;66(9):1873-8. PubMed PMID: 2224783.

  1. Cuenod CA, Bellin MF, Bousquet JC, Duron A, Auberton E, Mazoyer BM, Khayat D, Opolon P, Grellet J. MRI of liver tumors using gadolinium-DOTA: prospective study comparing spin-echo long TR-te sequence and CT. Magn Reson Imaging. 1991;9(2):235-45. PubMed PMID: 2034057.

  1. Kerbat P., Toussaint C, Goupil A, Rouesse J, Khayat D, Jacquillat C, Fernay M, Namer M, Cour V, Arcaute V, Berille J. Multicentric Phase II study of the nitrosourea Fotemustine in renal cell carcinoma : Preliminary results. Acta Medica,1991, 21: 329-332.

  1. Khayat D, Cour V, Bizzari JP, Aigner K, Borel C, Cohen-Alloro G, Weil M, Auclerc G, Buthiau D, Bousquet JC, et al. Fotemustine (S 10036) in the intra-arterial treatment of liver metastasis from malignant melanoma. A phase II Study. Am J Clin Oncol. 1991 Oct;14(5):400-4. Review. PubMed PMID: 1951178.

  1. Weil M, Borel C, Auclerc G, Baillet F, Khayat D. Nonsurgical approach in stage I and stage II breast cancer. Cancer Invest. 1992;10(6):581-6. Review. PubMed PMID: 1422893.

  1. Fournier C, Hecquet B, Bastian G, Khayat D. Modification of the physicochemical and pharmacological properties of anticancer platinum compounds by commercial 5-fluorouracil formulations: a comparative study using cisplatin and carboplatin. Cancer Chemother Pharmacol. 1992;29(6):461-6. PubMed PMID: 1568289.

  1. Khayat D, Borel C, Azab M, Paraisot D, Malaurie E, Bouloux C, Weil M. Phase I study of Datelliptium chloride, hydrochloride given by 24-h continuous intravenous infusion. Cancer Chemother Pharmacol. 1992;30(3):226-8. PubMed PMID: 1628372.

  1. Smith MJ and Khayat D. Residual acute confusional and hallucinatory syndromes induced by Interleukin-2/alpha interferon treatment. Psycho-Oncology, 1992, 1 : 115-118.

  1. Khayat D, Vuillement E. Treatment of malignant melanomas. Medicographa,1992, 14, 39-42.

  1. Khayat D, Borel C, Aigner K, Vuillement E, Cour V, Cohen-Aloro G, Vignoud J, Auclerc G, Weil M, Bizarri JP, Banzet P.Studies on hepatic intra-arterial infusion (HIAI) of fotemustine (FTMU).
    Reg Cancer Treat, 1992, 1-2: 1-5.

  1. Mouawad R, Visonneau S, Soubrane C, Hirel PH, Autran B, Marceau-Suissa J, Weil M, Khayat D. Antibodies raised against peptide fragments of CD16 reacting with membrane and soluble form of CD16. I: Production and characterization. Hybridoma. 1992 Aug;11(4):447-59. PubMed PMID: 1383125.

  1. Khayat D, Avril MF, Gerard B, Bertrand P, Bizzari JP, Cour V. Fotemustine: an overview of its clinical activity in disseminated malignant melanoma. Melanoma Res. 1992 Sep;2(3):147-51. Review. PubMed PMID: 1450667.

  1. Kaye SB, Khayat D, Aapro M, Diehl V. Who should receive a 5-HT3 antagonist? Lancet.1992 Oct 31; 340(8827):1107-8. PubMed PMID: 1357507.

  1. Soubrane C, Tourani JM, Andrieu JM, Visonneau S, Beldjord K, Israel-Biet D, Mouawad R, Bussel J, Weil M, Khayat D. Biologic response to anti-CD16 monoclonal antibody therapy in a human immunodeficiency virus-related immune thrombocytopenic purpura patient. Blood. 1993 Jan 1;81(1):15-9. PubMed PMID: 8093346.

  1. Khayat D, Antoine E, Rixe O, Tourani JM, Vuillemin E, Borel C, Benhammouda A, Thill L, Franks C, Auclerc G, et al. Chemoimmunotherapy of metastatic malignant melanoma. The Salpetriere Hospital (SOMPS) experience. Eur J Cancer. 1993;29A Suppl 5:S2-5. PubMed PMID: 8260262.

  1. Hoekstra A, Bassot V, Bertoglio S, Bobin JY, Delassus P, Egeli R, Khayat D, Ranchere JY, Santini J, Segol P. Clinical evaluation of the CORDIS vascular access port systems: a multicenter study. Med Oncol Tumor Pharmacother. 1993;10(3):131-8. PubMed PMID: 8264258.

  1. Lamour A, Soubrane C, Ichen M, Pennec YL, Khayat D, Youinou P. Fc-gamma receptor III shedding by polymorphonuclear cells in primary Sjogren’s syndrome. Eur J Clin Invest.1993 Feb;23(2):97-101. PubMed PMID: 8462626.

  1. Khayat D, Borel C, Tourani JM, Benhammouda A, Antoine E, Rixe O, Vuillemin E, Bazex PA, Thill L, Franks R, et al. Sequential chemoimmunotherapy with cisplatin, interleukin-2, and interferon alfa-2a for metastatic melanoma. J Clin Oncol. 1993 Nov;11(11):2173-80. PubMed PMID: 8229131.

  1. Salehian, T. Niyongabo, D. Salmon, J.L. Vilde, J.C. Melchior, D. Rigaud, Khayat D, Soubrane C. Tumor necrosis factor and resting energy expenditure during the acquired immunodeficiency syndrome. Am J Clinical Nutrition, 1993, 58 : 715-716.

  1. Khayat D, Giroux B, Berille J, Cour V, Gerard B, Sarkany M, Bertrand P, Bizzari JP. Fotemustine in the treatment of brain primary tumors and metastases. Cancer Invest.1994;12(4):414-20. Review. PubMed PMID: 8032964.

  1. Hutin P, Lamour A, Pennec YL, Soubrane C, Dien G, Khayat D, Youinou P. Cell-free Fc-gamma receptor III in sera from patients with systemic lupus erythematosus: correlation with clinical and biological features. Int Arch Allergy Immunol. 1994;103(1):23-7. PubMed PMID: 8260847.

  1. Soubrane C, Mouawad R, Ichen M, Suissa J, Borel C, Vuillemin E, Benhammouda A, Bizzari JP, Weil M, Khayat D. Follow up of soluble IL-2 receptor level in metastatic malignant melanoma patients treated by chemoimmunotherapy. Clin Exp Immunol. 1994 Feb;95(2):232-6. PubMed PMID: 8306497; PubMed Central PMCID: PMC1534932.

  1. Mouawad R, Ichen M, Rixe O, Benhammouda A, Vuillemin E, Weil M, Khayat D, Soubrane C. Study of IL-2 receptor expression after chemoimmunotherapy in patients treated for metastatic malignant melanoma. Clin Exp Immunol. 1994 Sep;97(3):342-6. PubMed PMID: 8082289; PubMed Central PMCID: PMC1534843.

  1. Bellin MF, Zaim S, Auberton E, Sarfati G, Duron JJ, Khayat D, Grellet J. Liver metastases: safety and efficacy of detection with superparamagnetic iron oxide in MR imaging. Radiology. 1994 Dec;193 (3) :657-63. PubMed PMID: 7972804.

  1. Smith MJ, Mouawad R, Vuillemin E, Benhammouda A, Soubrane Cl and Khayat D. Psychological side effects induced by interleukin-2/alpha IFN treatment. Psycho-Oncology1994, 3 : 289-298.

  1. Weil M, Smith MJ and Khayat D. Truth-telling to cancer patients in the Western European Context. Psycho-Oncology, 1994, 3 : 21-26.

  1. Boogaerts M, Cavalli F, Cortes-Funes H, Gatell JM, Gianni AM, Khayat D, Levy Y, Link H. Granulocyte growth factors: achieving a consensus. Ann Oncol. 1995 Mar;6(3):237-44. Review. PubMed PMID: 7542020.

  1. Rixe O, Borel C, Paraiso D, Benhammouda A, Petit T, Antoine E, Bizzari JP, Auclerc G, Soubrane C, Weil M, Giroux B, Banzet P, Khayat D. Fotemustine, dacarbazine, vindesine combination chemotherapy melanoma : a phase II study of 43 patients. Melanoma Research, 1995, 5 : 419-424.

  1. Khayat D. In : Docetaxel (taxotere) an advance in cancer management. Anti-Cancer Drugs, 1995, vol 6, supp 4 : 5-6.

  1. Khayt D. What is the role of Vindesine in Neoadjuvant Chemotherapy ? J.Drug Dev.Clin Prac, 1995, 7 : 141-150.

  1. Khayt D. Dose Intensity in Solid Tumours. Task Force Review, 1995, Issue 7.

  1. Khayt D. New directions in anti-cancer chemotherapy. Introduction. Seminars in Oncology, 1995, 22, 6 (14) : 1.

  1. Lamour A, Baron D, Soubrane C, Cartron J, Khayat D, Adler Y, Le Goff P, Youinou P. Anti-Fc gamma receptor III autoantibody is associated with soluble receptor in rheumatoid arthritis serum and synovial fluid. J Autoimmun. 1995 Apr;8(2):249-65. PubMed PMID: 7612151.

  1. Becherel PA, Chosidow O, Berger E, Martin S, Khayat D, Herson S, Frances C. Granulocyte-macrophage colony-stimulating factor in the management of severe ecthyma gangrenosum related to myelodysplastic syndrome. Arch Dermatol. 1995 Aug;131(8):892-4. PubMed PMID: 7632059.

  1. Mouawad R, Urien S, Soubrane C, Khayat D, Brandt R, Tillement JP, Bastian G. Comparison of the uptake of retinoids 13-cis-retinoic acid and Ro 13-6298 delivered to HL-60 cells by serum albumin or low-density lipoprotein. Cancer Chemother Pharmacol. 1996;38(2):198-201. PubMed PMID: 8616913.

  1. Antoine EC, Khayat D. European School of Oncology European consensus on the use of granulocyte colony-stimulating factor: the example of breast cancer. Cancer Chemother Pharmacol. 1996;38 Suppl:S103-9. Review. PubMed PMID: 8765428.

  1. Buthiau D, Antoine E, Piette JC, Nizri D, Baldeyrou P, Khayat D. Virtual tracheo-bronchial endoscopy: educational and diagnostic value. Surg Radiol Anat. 1996;18(2):125-31. PubMed PMID: 8782318.

  1. Boogaerts MA, Brugger W, Carella AM, Cortés-Funes H, Fibbe WE, Hows J, Khayat D, Linch DC, Link H, Moore MA, Testa NG. Peripheral blood progenitor cell transplantation: where do we stand? Chairman’s Summary of the European School of Oncology Task Force meeting Peripheral Blood progenitor cell’s held September 29-30, 1995. Ann Oncol. 1996;7 Suppl 2:1-4. Review. PubMed PMID: 8805940.

  1. Antoine EC, Khayat D. Dose intensification and breast cancer: current results and future perspectives. Ann Oncol. 1996;7 Suppl 2:31-40. Review. PubMed PMID: 8805947.

  1. Buthiau D, Antoine EC, Nizri D, Stefani E, Lucien P, Cohen-Aloro G, Gozy M, Guinet F, Chiche B, Weil M, Khayat D. The clinical measurement of volumes using helical CT. Surg Radiol Anat. 1996;18(3):227-31. PubMed PMID: 8873338.

  1. Saltz L, Shimada Y, Khayat D. CPT-11 (irinotecan) and 5-fluorouracil: a promising combination for therapy of colorectal cancer. Eur J Cancer. 1996;32A Suppl 3:S24-31. Review. PubMed PMID: 8943662.

  1. Calvez V, Rixe O, Wang P, Mouawad R, Soubrane C, Ghoumari A, Verola O, Khayat D, Colbere-Garapin F. Virus-free transfer of the herpes simplex virus thymidine kinase gene followed by ganciclovir treatment induces tumor cell death. Clin Cancer Res. 1996 Jan;2(1):47-51. PubMed PMID: 9816089.

  1. Petit T, Borel C, Rixe O, Avril MF, Monnier A, Giroux B, Weil M, Khayat D. Complete remission seven years after treatment for metastatic malignant melanoma. Cancer.1996 Mar 1;77(5):900-2. PubMed PMID: 8608481.

  1. Soubrane C, Mouawad R, Rixe O, Calvez V, Ghoumari A, Verola O, Weil M, Khayat D. Direct gene transfer of a plasmid carrying the herpes simplex virus-thymidine kinase gene (HSV-TK) in transplanted murine melanoma: in vivo study. Eur J Cancer. 1996 Apr;32A(4):691-5. PubMed PMID: 8695274.

  1. Lamour A, Le Corre R, Soubrane C, Khayat D, Youinou P. Anti-Fc gamma receptor autoantibodies from patients with Sjegren’s syndrome do not react with native receptor on human polymorphonuclear leukocytes. J Autoimmun. 1996 Apr;9(2):181-91. PubMed PMID: 8738962.

  1. Lamour A, LeCorre R, Jamin C, Soubrane C, Khayat D, Youinou P. Novel enzyme-linked immunosorbent assays for the detection of anti-Fc gamma receptor autoantibodies. Clin Diagn Lab Immunol. 1996 May;3(3):315-20. PubMed PMID: 8705676; PubMed Central PMCID: PMC170339.

  1. Audhuy B, Cappelaere P, Martin M, Cervantes A, Fabbro M, Rivière A, Khayat D, Bleiberg H, Faraldi M, Claverie N, Aranda E, Auclerc G, Audhuy B, Benhammouda A, Bleiberg H, Cals L, Cappelaere P, Cattan A, Cervantes A, Chevallier B, Conroy T, Cupissol D, De Greve J, Diaz-Rubio E, Seitz JF, et al. A double-blind, randomized comparison of the anti-emetic efficacy of two intravenous doses of dolasetron mesilate and granisetron in patients receiving high dose cisplatin chemotherapy. Eur J Cancer. 1996 May;32A(5):807-13. PubMed PMID: 9081358.

  1. Ghoumari AM, Rixe O, Yarovoi SV, Zerrouqi A, Mouawad R, Poynard T, Opolon P, Khayat D, Soubrane C. Gene transfer in hepatocarcinoma cell lines: in vitro optimization of a virus-free system. Gene Ther.1996 Jun;3(6):483-90. PubMed PMID: 8789797.

  1. Laccourreye O, Brasnu D, Bassot V, Menard M, Khayat D, Laccourreye H. Cisplatin-fluorouracil exclusive chemotherapy for T1-T3N0 glottic squamous cell carcinoma complete clinical responders: five-year results. J Clin Oncol.1996 Aug;14(8):2331-6. PubMed PMID: 8708725.

  1. Khayat D. Conclusion: the place of docetaxel (Taxotere) in future therapy. Anticancer Drugs. 1996 Aug;7 Suppl 2:53. PubMed PMID: 8862713.

  1. Mouawad R, Benhammouda A, Rixe O, Antoine EC, Borel C, Weil M, Khayat D, Soubrane C. Endogenous interleukin 6 levels in patients with metastatic malignant melanoma: correlation with tumor burden. Clin Cancer Res. 1996 Aug;2(8):1405-9. PubMed PMID: 9816314.

  1. Yarovoi SV, Mouawad R, Colbère-Garapin F, Soubrane C, Khayat D, Rixe O. In vitro sensitization of the B16 murine melanoma cells to ganciclovir by different RNA and plasmid DNA constructions encoding HSVtk. Gene Ther. 1996 Oct;3(10):913-8. PubMed PMID: 8908505.

  1. Zerrouqi A, Rixe O, Ghoumari AM, Yarovoi SV, Mouawad R, Khayat D, Soubrane C. Liposomal delivery of the herpes simplex virus thymidine kinase gene in glioma: improvement of cell sensitization to ganciclovir. Cancer Gene Ther. 1996 Nov-Dec;3(6):385-92. PubMed PMID: 8988841.

  1. Coeffic D, Benhammouda A, Antoine EC, Rixe O, Paraiso D, Auclerc G, Nizri D, Renody N, Grapin JP, Mularoni E, Rattini E, Soubrane C, Weil M, Mortier N, Khayat D. Phase I/II study of paclitaxel, cisplatin, and cyclophosphamide in advanced ovarian carcinoma: preliminary results. Semin Oncol. 1996 Dec;23(6 Suppl 15):5-8. PubMed PMID: 8996589.

  1. Chevallier B, Cappelaere P, Splinter T, Fabbro M, Wendling JL, Cals L, Catimel G, Giovannini M, Khayat D, Bastit P, Claverie N. A double-blind, multicentre comparison of intravenous dolasetron mesilate and metoclopramide in the prevention of nausea and vomiting in cancer patients receiving high-dose cisplatin chemotherapy. Support Care Cancer. 1997 Jan;5(1):22-30. PubMed PMID: 9010986.

  1. Coeffic D, Benhammouda A, Antoine EC, Rixe O, Paraiso D, Auclerc G, Renody N, Mularoni E, Soubrane C, Weil M, Mortier N, Khayat D. Preliminary results of a phase I/II study of paclitaxel, cisplatin, and cyclophosphamide in advanced ovarian carcinoma. Semin Oncol. 1997 Feb;24(1 Suppl 2):S2-38-S2-40. PubMed PMID: 9045335.

  1. Rixe O, Coeffic D, Orcel B, Maitre B, Borel C, Benhammouda A, Petit T, Khayat D, Derenne JP. A phase II study of cisplatin, 5-fluorouracil, leucovorin, and etoposide in advanced non-small-cell lung cancer. Am J Clin Oncol. 1997 Apr;20(2):128-31. PubMed PMID: 9124184.

  1. Khayat D, Antoine E. Dose intensification and breast cancer. Gan To Kagaku Ryoho. 1997 May;24 Suppl 1:153-77. Review. PubMed PMID: 9210898.

  1. Mouawad R, Khayat D, Zerrouqi A, Ghoumari AM, Soubrane C. A flow cytometric method for the rapid detection of beta-galactosidase transfected cells: an in vitro and in vivo study. J Immunol Methods. 1997 May 12;204(1):51-6. PubMed PMID: 9202709.

  1. Gatzemeier U, Manegold C, Eberhard W, Wilke HJ, Chomy F, Chomy P, Khayat D, Blatter J, Seeber S, Drings P. A phase II trial of gemcitabine and ifosfamide in non-small cell lung cancer. Semin Oncol. 1997 Jun;24(3 Suppl 8):S8-36-S8-38.PubMed PMID: 9207315.

  1. Antoine EC, Rixe O, Auclerc G, Weil M, Khayat D. Docetaxel. A review of its role in breast cancer treatment. Am J Clin Oncol. 1997 Aug;20(4):429-32. Review. PubMed PMID: 9256905. 

  1. Khayt D, Antoine EC, Benhammouda A, Delgado M, Rocher MA, Coeffic D, Nizri D, Soubrane, Auclerc G.Irinotecan (CPT11) based combination regimens in the treatment of advanced colorectal cancer.Advances in Colon Cancer, 1997, 5-7.

  1. Khayat D. Introduction: new directions in anticancer chemotherapy. Semin Oncol. 1997 Aug;24(4 Suppl 11):S11-1. PubMed PMID: 9314291.

  1. Khayat D, Antoine E. Docetaxel in combination chemotherapy for metastatic breast cancer. Semin Oncol.1997 Aug;24(4 Suppl 13):S13-19-S13-26. Review. PubMed PMID: 9335513.

  1. Bichat F, Mouawad R, Solis-Recendez G, Khayat D, Bastian G. Cytoskeleton alteration in MCF7R cells, a multidrug resistant human breast cancer cell line. Anticancer Res.1997 Sep-Oct;17(5A):3393-401. PubMed PMID: 9413178.

  1. Antoine EC, Benhammouda A, Bernard A, Youssef A, Mortier N, Gozy M, Nizri D, Auclerc G, Rocher MA, Soubrane CL, Weil M, Khayat D. Salpetriere Hospital experience with biochemotherapy in metastatic melanoma. Cancer J Sci Am. 1997 Dec;3 Suppl 1:S16-21. PubMed PMID: 9457388.

  1. Gatzemeier U, Manegold C, Eberhard W, Wilke HJ, Chomy F, Chomy P, Khayat D, Blatter J, Seeber S, Drings P. Ifosfamide and gemcitabine: a phase II trial in advanced inoperable non-small cell lung cancer. Semin Oncol. 1998 Feb;25(1 Suppl 2):15-8. PubMed PMID: 9535206.

  1. Mathurin P, Rixe O, Carbonell N, Bernard B, Cluzel P, Bellin MF, Khayat D, Opolon P, Poynard T. Review article: Overview of medical treatments in unresectable hepatocellular carcinoma–an impossible meta-analysis? Aliment Pharmacol Ther. 1998 Feb;12(2):111-26. PubMed PMID: 9692685.

  1. Khayat D, Gil-Delgado M, Antoine EC, Coeffic D, Benhammouda A, Grapin JP, Bastian G. European experience with irinotecan plus fluorouracil/folinic acid or mitomycin. Oncology (Williston Park). 1998 Aug;12(8 Suppl 6):64-7. Review. PubMed PMID: 9726094.

  1. Keilholz U, Conradt C, Legha SS, Khayat D, Scheibenbogen C, Thatcher N, Goey SH, Gore M, Dorval T, Hancock B, Punt CJ, Dummer R, Avril MF, Brucker EB, Benhammouda A, Eggermont AM, Pritsch M. Results of interleukin-2-based treatment in advanced melanoma: a case record-based analysis of 631 patients. J Clin Oncol. 1998 Sep;16(9):2921-9. PubMed PMID: 9738559.

  1. Bichat F, Solis-Recendez G, Poullain MG, Poupon MF, Khayat D, Bastian G. S9788 modulation of P-glycoprotein- and Multidrug-related protein-mediated multidrug resistance by Servier 9788 in doxorubicin-resistant MCF7 cells. Biochem Pharmacol. 1998 Aug 15;56(4):497-502. PubMed PMID: 9763226.

  1. Bouaud J, Saroussi B, Antoine EC, Gozy M, Khayat D, Boisvieux JF. Hypertextual navigation operationalizing generic clinical practice guidelines for patient-specific therapeutic decisions. Proc AMIA Symp. 1998:488-92. PubMed PMID: 9929267; PubMed Central PMCID: PMC2232063.

  1. Khayat D, Antoine EC. Breast cancer : paclitaxel in combination with other drugs.
    CME Journal of Gynecologic Oncology, 1998, chapter 9.

  1. Ghoumari AM, Mouawad R, Zerrouqi A, Nizard C, Provost N, Khayat D, Naus CC, Soubrane C. Actions of HSVtk and connexin43 gene delivery on gap junctional communication and drug sensitization in hepatocellular carcinoma. Gene Ther. 1998 Aug;5(8):1114-21. PubMed PMID: 10326035.

  1. Mouawad R, Khayat D, Merle S, Antoine EC, Gil-Delgado M, Soubrane C. Is there any relationship between interleukin-6/interleukin-6 receptor modulation and endogenous interleukin-6 release in metastatic malignant melanoma patients treated by biochemotherapy? Melanoma Res.1999 Apr;9(2):181-8. PubMed PMID: 10380941.

  1. Fauser AA, Pizzocaro G, Schueller J, Khayat D, Wilkinson P. A double-blind, randomised, parallel study comparing intravenous dolasetron plus dexamethasone and intravenous dolasetron alone for the management of fractionated cisplatin-related nausea and vomiting. Support Care Cancer. 2000 Jan;8(1):49-54. PubMed PMID: 10650898.

  1. Auclerc G, Antoine EC, Cajfinger F, Brunet-Pommeyrol A, Agazia C, Khayat D. Management of advanced prostate cancer. Oncologist.2000;5(1):36-44. Review. PubMed PMID: 10706648.

  1. Khayat D. Is anemia a problem for European cancer patients and treating oncologists? Semin Oncol. 2000 Apr;27(2 Suppl 4):9-11; discussion 16-7. Review. PubMed PMID: 10847302.

  1. Perez-Manga G, Lluch A, Alba E, Moreno-Nogueira JA, Palomero M, Garcia-Conde J, Khayat D, Rivelles N. Gemcitabine in combination with doxorubicin in advanced breast cancer: final results of a phase II pharmacokinetic trial. J Clin Oncol. 2000 Jul;18(13):2545-52. PubMed PMID: 10893285.

  1. Khayat D, Coeffic D. Chemotherapy and chemoimmunotherapy for metastatic malignant melanoma: review and recent advances. Gan To Kagaku Ryoho. 2000 May;27 Suppl 2:238-47. Review. PubMed PMID: 10895160.

  1. Soubrane C, Mouawad R, Antoine EC, Verola O, Gil-Delgado M, Khayat D. A comparative study of Fas and Fas-ligand expression during melanoma progression. Br J Dermatol. 2000 Aug;143(2):307-12. PubMed PMID: 10951137. 

  1. Khayt D. Non-small cell lung cancer in the year 2000. Anti-cancer drugs, 2000; vol. 11, supplement 1, S15. 

  1. Khayt D. Quality of life in cancer patients. Proceedings of a conference held in Vienna
    International Journal of Pharmaceutical medicine, 2000, 14 :69.

  1. Khayt D. The many causes of quality of life deficits in cancer patients
    International Journal of pharmaceutical medicine, 2000, 14 :70-73.

  1. Hortobagyi GN, Khayat D. Targeting progress: the development of growth factor receptor-directed therapy. Semin Oncol. 2000 Oct;27(5 Suppl 9):1-2. PubMed PMID: 11049050.

  1. Mouawad R, Khayat D, Soubrane C. Plasma Fas ligand, an inducer of apoptosis, and plasma soluble Fas, an inhibitor of apoptosis, in advanced melanoma. Melanoma Res.2000 Oct;10(5):461-7. PubMed PMID: 11095407.

  1. Khayat D, Auclerc G. Cancer in the elderly: are we ready? Curr Oncol Rep. 2000 Jul;2(4):279-80. PubMed PMID: 11122854.

  1. Mouawad R, Antoine EC, Khayat D, Soubrane C. Effect of endogenous interleukin-6 on Fas (APO-1/CD95) receptor expression in advanced melanoma patients. Cytokines Cell Mol Ther. 2000 Sep;6(3):135-40. PubMed PMID: 11140882.

  1. Khayat D, Antoine EC, Coeffic D. Taxol in the management of cancers of the breast and the ovary. Cancer Invest. 2000;18(3):242-60. Review. PubMed PMID: 10754992.

  1. Spano JP, Taillibert S, Khayat D, Terrier P. Hibernoma, an uncommon tumor as a differential diagnosis of liposarcoma of the thigh. Anticancer Res. 2000 Nov-Dec;20(6C):4803-4. PubMed PMID: 11205222.

  1. Taillibert S, Spano JP, Genestie C, Khayat D. A mesocolic leiomyosarcoma metastatic to the breast: case report and review of the literature. Anticancer Res.2000 Nov-Dec;20(6C):4867-9. Review. PubMed PMID: 11205234.

  1. Gil-Delgado MA, Guinet F, Castaing D, Adam R, Coeffic D, Durrani AK, Bismuth H, Khayat D. Prospective phase II trial of iriontecan, 5-fluorouracil, and leucovorin in combination as salvage therapy for advanced colorectal cancer. Am J Clin Oncol. 2001 Feb;24(1):101-5. PubMed PMID: 11232943.

  1. Khayat D, Gil-Delgado M, Antoine EC, Nizri D, Bastian G. The role of irinotecan and oxaliplatin in the treatment of advanced colorectal cancer. Oncology(Williston Park). 2001 Apr;15(4):415-29; discussion 429-30, 433-4. PubMed PMID: 11346931.

  1. Gil-Delgado MA, Antoine EC, Guinet F, Bassot V, Grapin JP, Benhammonda A, Adam R, Castaing D, Bismuth H, Khayat D. Phase I-II study of irinotecan in combination with mitomycin C in patients with advanced gastrointestinal cancer. Am J Clin Oncol. 2001 Jun;24(3):251-4. PubMed PMID: 11404495.

  1. Khayat D, Chollet P, Antoine EC, Monfardini S, Ambrosini G, Benhammouda A, Mazen MF, Sorio R, Borg-Olivier O, Riva A, Ramazeilles C, Azli N. Phase II study of sequential administration of docetaxel followed by doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breast cancer. J Clin Oncol. 2001 Jul 15;19(14):3367-75. PubMed PMID: 11454884.

  1. Khayat D. David Khayat: co-founder of The Charter of Paris Against Cancer (interview by Ezzie Hutchinson). Lancet Oncol. 2001 Apr;2(4):239-42. PubMed PMID: 11905771.

  1. Khayat D. Breast Cancer. Commentary , 2002,9, N°1.

  1. Khayat D.Overview of the role of chemotherapy in the management of metastatic breast cancer. Drugs of today, 2002, 38 (sup.A) : 3-10.

  1. Khayat D. Changes in perception of the unwanted effects of cancer chemotherapy: fatigue is becoming the new frontier. Drugs of today, 2002, 38 (sup.A), 69-77.

  1. Khayat D. The Charter of Paris Against Cancer–a major act marking an historical realization and turning point. Gan To Kagaku Ryoho. 2002 Feb;29 Suppl 1:47-9. PubMed PMID: 11890114.

  1. Marx GM, Steer CB, Harper P, Pavlakis N, Rixe O, Khayat D. Unexpected serious toxicity with chemotherapy and antiangiogenic combinations: time to take stock! J Clin Oncol.2002 Mar 15;20(6):1446-8. PubMed PMID: 11896090.

  1. Khayat D, Bernard-Marty C, Meric JB, Rixe O. Biochemotherapy for advanced melanoma: maybe it is real. J Clin Oncol. 2002 May 15;20(10):2411-4. PubMed PMID: 12011117.

  1. Steer CB, Marx GM, Galani E, Harper PG, Khayat D. Quality of life: it’s never too late. J Clin Oncol.2002 Jul 1;20(13):2915-7. PubMed PMID: 12089218.

  1. Carelle N, Piotto E, Bellanger A, Germanaud J, Thuillier A, Khayat D. Changing patient perceptions of the side effects of cancer chemotherapy. Cancer. 2002 Jul 1;95(1):155-63. PubMed PMID: 12115329.

  1. Mouawad R, Antoine EC, Gil-Delgado M, Khayat D, Soubrane C. Serum caspase-1 levels in metastatic melanoma patients: relationship with tumour burden and non-response to biochemotherapy. Melanoma Res. 2002 Aug;12(4):343-8. PubMed PMID: 12170183.

  1. Bajetta E, Del Vecchio M, Bernard-Marty C, Vitali M, Buzzoni R, Rixe O, Nova P, Aglione S, Taillibert S, Khayat D. Metastatic melanoma: chemotherapy. Semin Oncol. 2002 Oct;29(5):427-45. Review. PubMed PMID: 12407508.

  1. Khayat D, Rixe O, Martin G, Soubrane C, Banzet M, Bazex JA, Lauret P, Verola O, Auclerc G, Harper P, Banzet P; French Group of Research on Malignant Melanoma. Surgical margins in cutaneous melanoma (2 cm versus 5 cm for lesions measuring less than 2.1-mm thick. Cancer.2003 Apr 15;97(8):1941-6. PubMed PMID: 12673721.

  1. Spano J.P, Rixe O, Soubrane Cl, Mouawad R, Khayat D. Long term results of a large europena multicentric phase III study in cutaneous melanoma : surgical margins 2cm versus 5 cm for lesions measuring less thant 2.1 thick The American journal of oncology review, 2003, 2: 511-514.

  1. Harper P, Plunkett T, Khayat D. Quality trials and quality of life in non-small-cell lung cancer. J Clin Oncol.2003 Aug 15;21(16):3007-8. Epub 2003 Jul 1. PubMed PMID: 12837809.

  1. de Braud F, Khayat D, Kroon BB, Valdagni R, Bruzzi P, Cascinelli N. Malignant melanoma. Crit Rev Oncol Hematol. 2003 Jul;47(1):35-63. Review. PubMed PMID: 12853098.

  1. Mouawad R, Rixe O, Meric JB, Khayat D, Soubrane C. Serum interleukin-6 concentrations as predictive factor of time to progression in metastatic malignant melanoma patients treated by biochemotherapy: a retrospective study. Cytokines Cell Mol Ther. 2002;7(4):151-6. PubMed PMID: 14660055.

  1. Olaussen KA, Soria JC, Morat L, Martin A, Sabatier L, Morere JF, Khayat D, Spano JP. Loss of PTEN expression is not uncommon, but lacks prognostic value in stage I NSCLC. Anticancer Res. 2003 Nov-Dec;23(6C):4885-90. PubMed PMID: 14981940.

  1. Meric JB, Rixe O, Khayat D. Metastatic malignant melanoma. Drugs Today(Barc). 2003;39 Suppl C:17-38. Review. PubMed PMID: 14988744.

  1. Spano JP, Andre F, Morat L, Sabatier L, Besse B, Combadiere C, Deterre P, Martin A, Azorin J, Valeyre D, Khayat D, Le Chevalier T, Soria JC. Chemokine receptor CXCR4 and early-stage non-small cell lung cancer: pattern of expression and correlation with outcome. Ann Oncol. 2004 Apr;15(4):613-7. PubMed PMID: 15033669.

  1. Khayat D, Rixe O, Brunet R, Goupil A, Bugat R, Harousseau JL, Ifrah N, Puozzo C. Pharmacokinetic linearity of i.v. vinorelbine from an intra-patient dose escalation study design. Cancer Chemother Pharmacol. 2004 Sep;54(3):193-205. Epub 2004 May 25. PubMed PMID: 15160284.

  1. Gil-Delgado MA, Bastian G, Guinet F, Spano JP, Taillibert S, Rocher MA, Castaing D, Adam R, Urien S, Bismuth H, Khayat D. Oxaliplatin plus irinotecan and FU-FOL combination and pharmacokinetic analysis in advanced colorectal cancer patients. Am J Clin Oncol. 2004 Jun;27(3):294-8. PubMed PMID: 15170151.

  1. Berteretche MV, Dalix AM, d’Ornano AM, Bellisle F, Khayat D, Faurion A. Decreased taste sensitivity in cancer patients under chemotherapy. Support Care Cancer. 2004 Aug;12(8):571-6. Epub 2004 Jun 4. PubMed PMID: 15179562.

  1. Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, Chau I, Van Cutsem E. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med.2004 Jul 22;351(4):337-45. PubMed PMID: 15269313.

  1. Spano JP, Massiani MA, Bentata M, Rixe O, Friard S, Bossi P, Rouges F, Katlama C, Breau JL, Morere JF, Khayat D, Couderc LJ. Lung cancer in patients with HIV Infection and review of the literature. Med Oncol. 2004;21(2):109-15.Review. PubMed PMID: 15299182.

  1. Taflin C, Izzedine H, Launay-Vacher V, Rixe O, Khayat D, Deray G. Vincristine induced severe SIADH : potentiation with itraconazole Cancer Therapy, 2004, 2, 149-151. 

  1. Buthiau D, Rixe O, Spano JP, Nizri D, Delgado M, Gutierrez M, Bloch J, Bloch P, Rocher MA, Khayat D. New Imaging Techniques in oncology Eur Journal of cancer, 2003 Sup 1: 28-42. 

  1. Kerr D.J. and Khayat D. The Entente Cordiale – natural and necessary Ann of Oncol, 2004; 15:1581.

  1. Besse B, Cando C, Spano JP, Martin A, Khayat D, Le Chevalier T, Tursz T, Sabatier L, Soria JC, Kroemer G. Nuclear localization of apoptosis protease activating factor-1 predicts survival after tumor resection in early-stage non-small cell lung cancer. Clin Cancer Res. 2004 Sep 1;10(17):5665-9. PubMed PMID: 15355891.

  1. Spano JP, Lagorce C, Atlan D, Milano G, Domont J, Benamouzig R, Attar A, Benichou J, Martin A, Morere JF, Raphael M, Penault-Llorca F, Breau JL, Fagard R, Khayat D, Wind P. Impact of EGFR expression on colorectal cancer patient prognosis and survival. Ann Oncol. 2005 Jan;16(1):102-8. PubMed PMID: 15598946.

  1. Spano JP, Fagard R, Soria JC, Rixe O, Khayat D, Milano G. Epidermal growth factor receptor signaling in colorectal cancer: preclinical data and therapeutic perspectives. Ann Oncol.2005 Feb;16(2):189-94. Review. PubMed PMID: 15668269.

  1. Blohmer JU, Dunst J, Harrison L, Johnston P, Khayat D, Ludwig H, O’Brien M, Van Belle S, Vaupel P. Cancer-related anemia: biological findings, clinical implications and impact on quality of life. Oncology. 2005;68 Suppl 1:12-21. Review. PubMed PMID: 15855812.

  1. Soubrane C, Rixe O, Meric JB, Khayat D, Mouawad R. Pretreatment serum interleukin-6 concentration as a prognostic factor of overall survival in metastatic malignant melanoma patients treated with biochemotherapy: a retrospective study. Melanoma Res. 2005 Jun;15(3):199-204. PubMed PMID: 15917702.

  1. Boyle P, Ariyaratne M, Bartelink H, Baselga J, Berns A, Brawley OW, Burns H, Davidov M, Dinshaw KA, Dresler C, Eggermont AM, Gajurel D, Gordina G, Gray N, Kakizoe T, Karki BS, Kásler M, Kerr DJ, Khayat D, Kiselev A, Khuhaprema T, Klocker H, Levshin V, Martin-Moreno JM, McVie JG, Mendelsohn J, Napalkov NP, Ngoma TA, Park JG, Philip T, Potschke-Langer M, Poudal HN, Rajan B, Ringborg U, Rodger A, Seffrin JR, Shanta V, Shrestha MM, Thomas R, Tursz T, de Valeriola D, Veronesi U, Wiestler OD, Zaridze D, Zatonski W, Zeng YX. Curbing tobacco’s toll starts with the professionals: World No Tobacco Day. Lancet.2005 Jun 11-17;365(9476):1990-2. PubMed PMID: 15950704.

  1. Ludwig H, Khayat D, Giaccone G, Facon T. Proteasome inhibition and its clinical prospects in the treatment of hematologic and solid malignancies. Cancer.2005 Nov 1;104(9):1794-807. Review. PubMed PMID: 16178003.

  1. Bloch J, Rixe O, Meric JB, Delgado A, Khayat D. Comparison of the efficacy and safety of combinations of metopimazine or ondansetron with methylprednisolone in the prevention of delayed emesis in patients receiving chemotherapy. Curr Med Res Opin. 2005 Nov;21(11):1763-71. PubMed PMID: 16307696.

  1. Meric JB, Rottey S, Olaussen K, Soria JC, Khayat D, Rixe O, Spano JP. Cyclooxygenase-2 as a target for anticancer drug development. Crit Rev Oncol Hematol.2006 Jul;59(1):51-64. Epub 2006 Mar 13. Review. PubMed PMID: 16531064.

  1. Boyle P, Ariyaratne MA, Barrington R, Bartelink H, Bartsch G, Berns A, de Valeriola D, Dinshaw KA, Eggermont AM, Gray N, Kakizoe T, Karki BS, Kaslar M, Kerr DJ, Khayat D, Khuhaprema T, Kim IH, Martin-Moreno J, McVie G, Park JG,Philip T, Ringborg U, Rodger A, Seffrin JR, Semiglazov V, Soo KC, Sun YT, Thomas R, Tursz T, Veronesi U, Wiestler O, Yoo KY, Zatonski W, Zhao P. Tobacco: deadly in any form or disguise. Lancet.2006 May 27;367(9524):1710-2. PubMed PMID: 16731252.

  1. Mouawad R, Soubrane C, Rixe O, Khayat D, Spano JP. An unexpected inverse correlation between soluble epidermal growth factor receptor and interleukin-6 in metastatic malignant melanoma patients. Melanoma Res.2006 Aug;16(4):335-40. PubMed PMID: 16845329.

  1. Khayat D, Kerr D. A new model for cancer research in France. Nat Rev Cancer. 2006 Aug;6(8):645-51. PubMed PMID: 16862194.

  1. Gil Delgado M, Spano JP, Khayat D. Cetuximab plus irinotecan in refractory colorectal cancer patients. Expert Rev Anticancer Ther. 2007 Apr;7(4):407-13.Review. PubMed PMID: 17428161.

  1. Gligorov J, Azria D, Namer M, Khayat D, Spano JP. Novel therapeutic strategies combining antihormonal and biological targeted therapies in breast cancer: focus on clinical trials and perspectives. Crit Rev Oncol Hematol. 2007 Nov;64(2):115-28. Epub 2007 Aug 16. Review. PubMed PMID: 17702596.

  1. Patel PM, Sim S, O’Donnell DO, Protheroe A, Beirne D, Stanley A, Tourani JM, Khayat D, Hancock B, Vasey P, Dalgleish A, Johnston C, Banks RE, Selby PJ. An evaluation of a preparation of Mycobacterium vaccae (SRL172) as an immunotherapeutic agent in renal cancer. Eur J Cancer. 2008 Jan;44(2):216-23. PubMed PMID: 18164612.

  1. Spano JP, Milano G, Vignot S, Khayat D. Potential predictive markers of response to EGFR-targeted therapies in colorectal cancer. Crit Rev Oncol Hematol. 2008 Apr;66(1):21-30. Epub 2008 Feb 21. Review. PubMed PMID: 18206383.

  1. Spano JP, Khayat D. Treatment options for anemia, taking risks into consideration: erythropoiesis-stimulating agents versus transfusions. Oncologist. 2008;13 Suppl 3:27-32. Review. PubMed PMID: 18458122.

  1. Spano JP, Costagliola D, Katlama C, Mounier N, Oksenhendler E, Khayat D. AIDS-related malignancies: state of the art and therapeutic challenges. J Clin Oncol. 2008 Oct 10;26(29):4834-42. Epub 2008 Jun 30. Review. PubMed PMID: 18591544.

  1. Boyle P, Anderson BO, Andersson LC, Ariyaratne Y, Auleley GR, Barbacid M, Bartelink H, Baselga J, Behbehani K, Belardelli F, Berns A, Bishop J, Brawley O, Burns H, Clanton M, Cox B, Currow D, Dangou JM, de Valeriola D, Dinshaw K, Eggermont A, Fitzpatrick J, Forstmane M, Garaci E, Gavin AT, Kakizoe T, Kasler M, Keita N, Kerr D, Khayat D, Khleif S, Khuhaprema T, Knezevic T, Kubinova R, Mallath M, Martin-Moreno J, McCance D, McVie JG, Merriman A, Ngoma T, Nowacki M, Orgelbrand J, Park JG, Pierotti M, Ashton LP, Puska P, Escobar CV, Rajan B, Rajkumar T, Ringborg U, Robertson C, Rodger A, Roovali L, Santini LA, Sarhan M, Seffrin J, Semiglazov V, Shrestha BM, Soo KC, Stamenic V, Tamblyn C, Thomas R, Tuncer M, Tursz T, Vaitkiene R, Vallejos C, Veronesi U, Wojtyla A, Yach D, Yoo KY, Zatonski W, Zaridze D, Zeng YX, Zhao P, Zheng T. Need for global action for cancer control. Ann Oncol. 2008 Sep;19(9):1519-21. PubMed PMID: 18723552.

  1. Michels J, Spano JP, Brocheriou I, Deray G, Khayat D, Izzedine H. Acute Tubular Necrosis and Interstitial Nephritis during Pemetrexed Therapy. Case Rep Oncol. 2009 Mar 14;2(1):53-56. PubMed PMID: 20740145; PubMed Central PMCID: PMC2918829.

  1. Izzedine H, Ederhy S, Goldwasser F, Soria JC, Milano G, Cohen A, Khayat D, Spano JP. Management of hypertension in angiogenesis inhibitor-treated patients. Ann Oncol. 2009 May;20(5):807-15. Epub 2009 Jan 15. Review. PubMed PMID: 19150949.

  1. Mouawad R, Spano JP, Comperat E, Capron F, Khayat D. Tumoural expression and circulating level of VEGFR-3 (Flt-4) in metastatic melanoma patients: correlation with clinical parameters and outcome. Eur J Cancer. 2009 May;45(8):1407-14. Epub 2009 Jan 20. PubMed PMID: 19157860.

  1. Izzedine H, Boostandoot E, Spano JP, Bardier A, Khayat D. Temsirolimus-induced glomerulopathy. Oncology. 2009;76(3):170-2. Epub 2009 Feb 12. PubMed PMID: 19212144.

  1. Vignot S, Khayat D. A step in the journey of denosumab from bone-targeted therapy to seed- and soil-targeted therapy. J Clin Oncol. 2009 Apr 1;27(10):1534-6. Epub 2009 Feb 23. PubMed PMID: 19237628.

  1. Izzedine H, Bahleda R, Khayat D, Massard C, Magne N, Spano JP, Soria JC.Electrolyte disorders related to EGFR-targeting drugs. Crit Rev Oncol Hematol.2010 Mar;73(3):213-9. Epub 2009 Apr 28. Review. PubMed PMID: 19403315.

  1. Van Cutsem E, Labianca R, Bodoky G, Barone C, Aranda E, Nordlinger B, Topham C, Tabernero J, Andre T, Sobrero AF, Mini E, Greil R, Di Costanzo F, Collette L, Cisar L, Zhang X, Khayat D, Bokemeyer C, Roth AD, Cunningham D. Randomized phase III trial comparing biweekly infusional fluorouracil/ leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3. J Clin Oncol. 2009 Jul 1;27(19):3117-25. Epub 2009 May 18. PubMed PMID: 19451425.

  1. Mouawad R, Sebert M, Michels J, Bloch J, Spano JP, Khayat D. Treatment for metastatic malignant melanoma: old drugs and new strategies. Crit Rev Oncol Hematol. 2010 Apr;74(1):27-39. Epub 2009 Sep 24. Review. PubMed PMID: 19781957.

  1. Izzedine H, Massard C, Spano JP, Goldwasser F, Khayat D, Soria JC. VEGF signalling inhibition-induced proteinuria: Mechanisms, significance and management. Eur J Cancer. 2010 Jan;46(2):439-48. Epub 2009 Dec 16. Review. PubMed PMID: 20006922.

  1. Mouawad R, Spano JP, Khayat D. Old and new serological biomarkers in melanoma: where we are in 2009. Melanoma Res. 2010 Apr;20(2):67-76. Review. PubMed PMID: 20093989.

  1. Magne N, Chargari C, MacDermed D, Conforti R, Védrine L, Spano JP, Khayat D.Tomorrow’s targeted therapies in breast cancer patients: what is the risk for increased radiation-induced cardiac toxicity? Crit Rev Oncol Hematol. 2010 Dec;76(3):186-95. Epub 2010 Feb 6. Review. PubMed PMID: 20138541.

  1. Soria JC, Smit E, Khayat D, Besse B, Yang X, Hsu CP, Reese D, Wiezorek J, Blackhall F. Phase 1b study of dulanermin (recombinant human Apo2L/TRAIL) in combination with paclitaxel, carboplatin, and bevacizumab in patients with advanced non-squamous non-small-cell lung cancer. J Clin Oncol. 2010 Mar 20;28(9):1527-33. Epub 2010 Feb 16. PubMed PMID: 20159815.

  1. Barete S, Mouawad R, Choquet S, Viala K, Leblond V, Musset L, Amoura Z, Khayat D, Francais C. Skin manifestations and vascular endothelial growth factor levels in POEMS syndrome: impact of autologous hematopoietic stem cell transplantation. Arch Dermatol. 2010 Jun;146(6):615-23. PubMed PMID: 20566924.

  1. Mouawad R, Spano JP, Khayat D. Paving the way to the cure of melanoma.Melanoma Res. 2010 Dec; 20(6):441-2. PubMed PMID: 21045619.

  1. Tempero MA, Berlin J, Ducreux M, Haller D, Harper P, Khayat D, Schmoll HJ,Sobrero A, Van Cutsem E. Pancreatic cancer treatment and research: an international expert panel discussion. Ann Oncol. 2011 Jan 3. [Epub ahead ofprint] PubMed PMID: 21199884.

  1. De Sanctis A, Taillade L, Vignot S, Novello S, Conforti R, Spano JP, Scagliotti GV, Khayat D. Pulmonary toxicity related to systemic treatment ofnonsmall cell lung cancer. Cancer. 2011 Jan 31. doi: 0.1002/cncr.25894. [Epub ahead of print] PubMed PMID: 21283982.

  1. Soria JC, Blay JY, Spano JP, Pivot X, Coscas Y, Khayat D. Added value of molecular targeted agents in oncology. Ann Oncol.2011 Feb 7. [Epub ahead of print] PubMed PMID: 21300696.

  1. Mouawad R, Spano JP, Khayat D. Lymphocyte Infiltration in Breast Cancer: A Key Prognostic Factor That Should Not Be Ignored. J Clin Oncol.2011 Apr 11. [Epub ahead of print] PubMed PMID: 21482993.